rs2270915 — NPR3 N521D

Your heart is not only a pump — it is an endocrine organ. When the cardiac chambers come under pressure, they release natriuretic peptides¹¹ natriuretic peptides
ANP (atrial), BNP (ventricular), and CNP (endothelial) — small hormones that dilate blood vessels, trigger renal sodium excretion, and suppress the renin-angiotensin-aldosterone system. Three receptors govern how the body responds to these signals. NPR1 and NPR2 activate protective cGMP signaling. NPR3 (also called NPR-C) acts as the clearance receptor — it binds natriuretic peptides and internalizes them for degradation, regulating how much active peptide reaches the other receptors. But NPR3 does more than mop up spare peptides: its intracellular domain couples to inhibitory Gi proteins, suppressing cAMP production inside cardiac cells and modulating fibroblast proliferation. The rs2270915 variant disrupts exactly this second function.

The N521D substitution (c.1561A>G) places an aspartate where asparagine normally sits at position 521, within the 17-amino-acid cytoplasmic catalytic domain²² 17-amino-acid cytoplasmic catalytic domain that couples to Gi. This is not the peptide-binding extracellular domain — so the receptor still clears natriuretic peptides normally. Instead, the disruption alters intracellular cAMP regulation within cardiac myocytes and fibroblasts.

When Gi coupling is impaired, adenylyl cyclase is less inhibited, shifting the balance toward elevated cAMP in contexts where NPR-C normally suppresses it. Laboratory cells carrying the AG genotype showed significantly lower NPR3 mRNA expression and reduced ANP clearance from the medium compared with AA cells, suggesting the variant also reduces receptor expression — likely via subtle changes in protein stability. Combined, these effects alter the signaling environment in the myocardium in ways that promote cardiac fibroblast proliferation and extracellular matrix remodeling³³ extracellular matrix remodeling, contributing to the stiffened ventricular wall that characterizes diastolic dysfunction.

The primary human evidence comes from the Prevalence of Asymptomatic Ventricular Dysfunction (PAVD) study⁴⁴ Prevalence of Asymptomatic Ventricular Dysfunction (PAVD) study
A cross-sectional, community-based echocardiography study of 1,931 randomly selected residents of Olmsted County, Minnesota, aged ≥45 years. After comprehensive echocardiographic assessment, diastolic dysfunction was found in 43% of GG homozygotes versus 28% of AA+AG individuals (p=0.007). Multivariate logistic regression adjusting for age, sex, BMI, and hypertension confirmed the independent association: OR 1.94 (95% CI 1.07–3.51, p=0.03). Importantly, there were no significant differences in circulating ANP or BNP levels between genotypes, confirming that the effect operates through signaling — not clearance.

In two large European diabetic cohorts (DIABHYCAR n=3,126; D2NG/SDG n=2,452), the G allele was consistently associated with higher systolic blood pressure than the AA genotype [21464461]. The most striking finding from a mechanistic standpoint came from a small physiological intervention (n=14): AA homozygotes had a −20 mmHg systolic reduction on strict salt restriction, while G carriers achieved only −3 mmHg (p=0.006). The G allele nearly abolishes the blood pressure benefit of sodium reduction.

Molecular characterization in a multi-ethnic resequencing study of 288 healthy individuals confirmed that AG heterozygote cells produce less NPR3 mRNA than AA cells and clear less ANP from the surrounding medium [23493048].

For GG homozygotes (about 4% of Europeans), the evidence is clearest: diastolic function warrants periodic echocardiographic monitoring, particularly after age 45. Salt restriction offers substantially less blood pressure benefit than in AA individuals, so other mechanisms (weight reduction, RAAS modulation) take precedence. Avoiding conditions that stress diastolic filling — uncontrolled hypertension, obesity, sleep apnea — carries additional importance given the elevated baseline risk.

For AG heterozygotes, the elevation in risk is proportionally lower but still present. The same logic around salt restriction applies: the G allele dampens the natriuretic peptide response to sodium loading, meaning standard "eat less salt" advice delivers less return than it would for AA individuals.

The NPR3 locus is functionally linked to its upstream pathway partners. The NPPA gene (rs5068) encodes atrial natriuretic peptide itself; rs5068 minor G allele carriers produce more ANP, providing a degree of pathway compensation that may partially offset NPR3 dysfunction. At the population GWAS level, rs1173727 in the NPR3 promoter region tags a separate signal associated with blood pressure and left atrial volume — illustrating that NPR3 expression level and protein function are both independently regulated. Clinically, the NPR3 locus overlaps with height GWAS signals, reflecting the role of natriuretic peptides in skeletal growth (via CNP/NPR-B), unrelated to the cardiovascular phenotypes relevant here.